Industry News

Cellect Biotechnology Ltd., a developer of innovative technology which enables the functional selection of stem cells, today announced the pricing of its initial public offering in the United States of 1,292,308 American Depository Shares and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary shares of the Company, and each warrant to purchase ADSs are offered at a combined price to the public of $6.50."/>
Cellect Biotechnology Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered into definitive subscription agreements with investors pursuant to a registered direct offering for total gross proceeds of approximately $11.1 million. The closing of the transaction is expected to occur on..."/>
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, announced plans to release its financial results for the second quarter of 2016 on August 5, 2016 before the opening of the financial markets. Roka Bioscience will also host a conference call at 8:30 a.m. Eastern Time on August 5, 2016 to discuss its second quarter financial results."/>
Roka Bioscience to Report Second Quarter 2016 Financial Results On August 5, 2016
NOVADAQ Technologies Inc., the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today that management will participate in two investor conferences in August.. Canaccord Genuity 36th Annual Growth Conference: NOVADAQ is scheduled to present on Wednesday, August 10 at 4:00 p.m. Eastern Time at the InterContinental Hotel in Boston, MA. 2016 Wedbush PacGrow..."/>
NOVADAQ to Participate in August Investor Conferences
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Monday, August 1, 2016 at 8:30 a.m. ET to discuss its second quarter 2016 financial results and provide a company update.. To participate in the conference call, please dial 1-888-396-2320, 1-774-264-7560 and refer to conference ID: 58777481."/>
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2016 Financial Results on Monday, August 1, 2016
Ligand Pharmaceuticals Incorporated announces the signing of a license agreement for three programs utilizing Ligand’ s LTP technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China. Ligand’ s LTP technology is a novel prodrug..."/>
Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
Aetna and Humana, and Cigna and Anthem, have raised divergent views on who benefits and who might be harmed. Both Aetna and Anthem say they will vigorously fight lawsuits by the Justice Department seeking to prevent the proposed $37 billion purchase of Humana Inc. by Hartford-based Aetna Inc. and a $54 billion deal in which Anthem Inc. would buy Bloomfield-based Cigna Corp.."/>
When Big Insurance Companies Merge, Who Benefits? [The Hartford Courant]
Semler Scientific, Inc., an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups, today reported financial results for the second quarter and year-to-date ended June 30, 2016.. "Clients have begun to migrate to QuantaFlo™, our latest cardiovascular product, from our lower-priced predecessor product," said Doug Murphy-Chutorian, M.D.,..."/>
Semler Reports Second Quarter and Year-to-date 2016 Financial Results
Aphria Inc. is pleased to announce today that, due to strong demand, it has agreed with a syndicate of underwriters led by Clarus Securities Inc., to increase the size of its previously announced $25,000,000 "bought deal" offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a "bought deal" basis, 15,000,000 common shares of the Company, at a price of C..."/>
Aphria Inc. Announces Increase to Bought Deal Financing
Editas Medicine, Inc., a leading genome editing company, announced today the appointment of Akshay Vaishnaw, M.D., Ph.D., to its board of directors. Vaishnaw is Executive Vice President of Research and Development and Chief Medical Officer at Alnylam Pharmaceuticals, Inc.. “I am delighted to welcome Akshay to our board of directors,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine.“ He has extensive clinical development..."/>
Editas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors
NewLink Genetics Corporation, a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients, today reported consolidated financial results for the second quarter of 2016 and provided updates on its clinical development programs and operational restructuring."/>
NewLink Genetics Reports Second Quarter 2016 Financial Results
Sanofi Announces Q2 2016 Results
Sientra, Inc., a medical aesthetics company, announced today that the Company will release its second quarter 2016 financial results on Tuesday, August 9, 2016 before the market opens.. Sientra will hold a conference call on Tuesday, August 9, 2016 at 5:30 a.m. PT/8: 30 a.m. ET to discuss the results."/>
Sientra® to Release Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9, 2016
Dextera Surgical Inc. today announced that it will release financial results for its fiscal fourth quarter and full year ended June 30, 2016, on Tuesday, August 9, 2016, after the markets close. Dextera Surgical’ s management will host a conference call, which will include a brief presentation and question and answer session with Joel Dunning, M.D., at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company’ s..."/>
Dextera Surgical to Announce Fiscal 2016 Fourth Quarter Financial Results on Tuesday, August 9, 2016
AbbVie announced financial results for the second quarter ended June 30, 2016.. "AbbVie continues to deliver on our long-term strategy, as demonstrated by our sixth consecutive quarter of double digit sales and earnings growth," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "A key element to our long-term sustainable performance is our advancing pipeline and this quarter we saw several regulatory approvals,..."/>
AbbVie Reports Second-Quarter 2016 Financial Results
Sunesis Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2016. Loss from operations for the three months ended June 30, 2016 was $10.0 million. As of June 30, 2016, cash, cash equivalents and marketable securities totaled $33.1 million."/>
Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights
IRADIMED CORPORATION, the only known provider of non-magnetic intravenous infusion pump systems that are designed to be safe for use during magnetic resonance imaging..."/>
IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results
Shire plc today announced that the United States Food and Drug Administration has granted Fast Track designation for SHP626 for an investigational treatment of adults who have nonalcoholic steatohepatitis with liver fibrosis. Shire is developing SHP626 as a once daily, orally-administered inhibitor of the apical sodium dependent bile acid transporter, a protein which is primarily responsible for recycling bile acids..."/>
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today announced interim 8- week results from the ongoing SER-109 Phase 2 ECOSPOR TM clinical study for the prevention of multiply recurrent Clostridium difficile infection."/>
Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
Ventas, Inc. today announced strong earnings on a healthy balance sheet for the second quarter of 2016, driven by excellent performance from the Company’ s high-quality healthcare and senior living properties and accretive acquisitions:."/>
Ventas Reports 2016 Second Quarter Results
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider, PCT, with a select therapeutic development pipeline, announces today that its product candidate CLBS03 was granted Fast Track designation by the US Food and Drug Administration for the treatment of type 1 diabetes mellitus, making it the first known therapeutic candidate for treatment of T1D to receive the designation."/>
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Merck Announces Second-Quarter 2016 Financial Results
Acadia Healthcare Company, Inc. today announced financial results for the second quarter and six months ended June 30, 2016."/>
Acadia Healthcare Reports Second Quarter GAAP EPS of $0.65 and Adjusted EPS of $0.73, up 28.1%

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials960 Articles
Information Technology909 Articles
Consumer Discretionary766 Articles
Industrials600 Articles
Health Care598 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at